check_circleStudy Completed

Female contraception

DRSP Wafer: Rel. BA DRSP + buccal E2

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

45 - 75 Years
  • -

  • -

Trial summary

Enrollment Goal
12
Trial Dates
November 2009 - January 2010
Phase
Phase 1
Could I Receive a placebo
N/A
Products
DRSP Ring (BAY86-4888)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer Pharma AGBerlin, 13353, Germany

Trial design

An exploratory, open-label, single-dose, randomized, crossover study investigating the relative bioavailability of drospirenone (DRSP) and estradiol (E2) after oral single dose administration of 3 mg DRSP and 90 μg E2 as a wafer formulation versus a marketed tablet (ANGELIQ) in 12 healthy postmenopausal women
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A